ArticleBMC medicine2018
Zika vaccines and therapeutics: landscape analysis and challenges ahead.
Article in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 87 citations in OpenAlex.
- Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.The Lancet. Infectious diseases · 2023Trial
- Synchronous Fluorescence Spectroscopy to Monitor Relevant Biochemicals over Zika-Virus-Like Particles' Production.Journal of fluorescence · 2026Article
- Immunoinformatics-Based Design of Multi-epitope DNA and mRNA Vaccines Against Zika Virus.Bioinformatics and biology insights · 2024Article
- Seroprevalence of Zika in Brazil stratified by age and geographic distribution.Epidemiology and infection · 2023Article
- Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.PLoS neglected tropical diseases · 2022Article
- Zika M-A Potential Viroporin: Mutational Study and Drug Repurposing.Biomedicines · 2022Article
- Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement.Frontiers in immunology · 2022Article
- Yellow fever vaccine protects mice against Zika virus infection.PLoS neglected tropical diseases · 2021Article
- The legacy of ZikaPLAN: a transnational research consortium addressing Zika.Global health action · 2021Review
- Review
- Review
- Review
- Palmitoleate Protects against Zika Virus-Induced Placental Trophoblast Apoptosis.Biomedicines · 2021Article
- Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection.Frontiers of medicine · 2021Review
- Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.PLoS neglected tropical diseases · 2021Article
- Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response.Frontiers in immunology · 2021Review
- Contemporary Understanding of Ebola and Zika Virus in Pregnancy.Clinics in perinatology · 2020Review
- Reverse genetic approaches for the development of Zika vaccines and therapeutics.Current opinion in virology · 2020Review
- Antiviral Natural Products for Arbovirus Infections.Molecules (Basel, Switzerland) · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
Abstract
backgroundVarious Zika virus (ZIKV) vaccine candidates are currently in development. Nevertheless, unique challenges in clinical development and regulatory pathways may hinder the licensure of high-quality, safe, and effective ZIKV vaccines. DISCUSSION: Implementing phase 3 efficacy trials will be difficult given the challenges of the spatio-temporal heterogeneity of ZIKV transmission, the unpredictability of ZIKV epidemics, the broad spectrum of clinical manifestations making a single definite endpoint difficult, a lack of sensitive and specific diagnostic assays, and the need for inclusion of vulnerable target populations. In addition to a vaccine, drugs for primary prophylaxis, post-exposure prophylaxis, or treatment should also be developed to prevent or mitigate the severity of congenital Zika syndrome.
conclusionEstablishing the feasibility of immune correlates and/or surrogates are a priority. Given the challenges in conducting phase 3 trials at a time of waning incidence, human challenge trials should be considered to evaluate efficacy. Continued financial support and engagement of industry partners will be essential to the successful development, licensure, and accessibility of Zika vaccines or therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.